Sarepta To Pay $35M Plus Royalties In Exondys Patent Dispute
By Kat Greene ( July 18, 2017, 8:07 PM EDT) -- Sarepta Therapeutics Inc. said Tuesday it has agreed to shell out $35 million plus royalties and payments for additional regulatory and commercial milestones to end a patent fight with BioMarin Pharmaceutical Inc. over the technology that backs Sarepta's recently approved Exondys 51....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.